To Sollve The Financial Matter Of The Pharmaceuticals

Pharmaceutical industry is a high technology,high-risk and high-profit industries,in China,pharmaceutical companies have a great gap comparing with developed countries,at the same time it is vital to the national drug strategic commodities,and it is very important to the daily lives of people.So supporting the Chinese Pharmaceutical industry is a major act of revitalizing the national economy,and it should be develop and create a multi-channel means of financing pharmaceutical enterprises by increasing capital investment in the pharmaceutical industry.The purpose of the paper is to explore solutions to difficulties in financing China's pharmaceutical enterprises in connection with the pharmaceutical industry for high-risk,high profit,characteristics of financing,corporating finance at home and abroad means and studying the characteristics and experiences,in that way we utilize the basic financial principles and integration of financial derivatives principle to design the effective channels in solving the problem of fund shortage.In this paper,I use some methods to introduce the definition of the approach in financing,to study the theory of Chinese pharmaceutical enterprises in the financing,analysing the financial status and issues what pharmaceutical companies are facing in modern times.Then study the feasibility of financing and determine the macro design by combining with domestic and foreign advanced theory of corporate finance experience.This paper proposes four new financing channels which are suitable for China's pharmaceutical enterprises through the above-mentioned studies to solve the lack of fund,the pharmaceutical companies'cash flow problem,the pharmaceutical's R&D and M&A fund in Private equity and Securitization of intellectual property rights.On the basis of efficient use of capital we can improve operational efficiency and profitability,established the mode of financing for China's pharmaceutical industry which are in line with the characteristics of China's pharmaceutical enterprises.And it will inject new blood and vitality into the future development of our pharmaceutical industry.